BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+2.31%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$3.71B
AUM Growth
+$3.71B
(+3.4%)
Cap. Flow
+$214M
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
63.73%
Holding
72
New
5
Increased
7
Reduced
10
Closed
3
Top Buys
| 1 |
Mirum Pharmaceuticals
MIRM
|
$138M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$52.6M |
| 3 |
Protagonist Therapeutics
PTGX
|
$32.8M |
| 4 |
Roivant Sciences
ROIV
|
$32M |
| 5 |
Merus
MRUS
|
$27.1M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
$63M |
| 2 |
MTEM
Molecular Templates, Inc.
MTEM
|
$28.2M |
| 3 |
IDEAYA Biosciences
IDYA
|
$10.8M |
| 4 |
Galapagos
GLPG
|
$8.64M |
| 5 |
Relay Therapeutics
RLAY
|
$6.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.24B | 33.43% | 21,751,284 | – | – |
|
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $182M | 4.9% | 4,004,613 +1,158,598 | +41% | +$52.6M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $149M | 4.02% | 2,131,100 | – | – |
|
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $143M | 3.84% | 5,283,489 -400,000 | -7% | -$10.8M |
|
|
5
Mirum Pharmaceuticals
MIRM
$3.71B
| $138M | 3.72% | +4,370,024 | New | +$138M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $113M | 3.04% | 9,135,893 +1,524,390 | +20% | +$18.8M |
|
|
7
Revolution Medicines
RVMD
$7.1B
| $110M | 2.97% | 3,981,212 -2,274,376 | -36% | -$63M |
|
8
Repare Therapeutics
RPTX
$71.7M
| $100M | 2.7% | 8,291,988 | – | – |
|
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $95.8M | 2.58% | 5,744,848 +1,968,948 | +52% | +$32.8M |
|
10
GH Research
GHRS
$837M
| $93.2M | 2.51% | 9,275,158 | – | – |
|
11
Structure Therapeutics
GPCR
$1.11B
| $88.2M | 2.38% | 1,750,000 | – | – |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $70.5M | 1.9% | 10,563,748 | – | – |
|
|
13
Galapagos
GLPG
$2.07B
| $66.2M | 1.78% | 1,915,109 -250,000 | -12% | -$8.64M |
|
14
Kymera Therapeutics
KYMR
$2.95B
| $65.9M | 1.78% | 4,739,004 | – | – |
|
|
15
Merus
MRUS
$4.98B
| $64.9M | 1.75% | 2,752,420 +1,150,000 | +72% | +$27.1M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $62.4M | 1.68% | 1,827,958 | – | – |
|
17
Kura Oncology
KURA
$686M
| $61.4M | 1.66% | 6,730,983 | – | – |
|
|
CNTA
18
Centessa Pharmaceuticals
CNTA
$2.25B
| $58.9M | 1.59% | 9,103,054 -320,161 | -3% | -$2.07M |
|
19
Xoma
XOMA
$392M
| $51.2M | 1.38% | 3,633,743 | – | – |
|
20
4D Molecular Therapeutics
FDMT
$288M
| $51M | 1.38% | 4,007,413 | – | – |
|
21
Aclaris Therapeutics
ACRS
$209M
| $48.4M | 1.31% | 7,064,736 +3,703,795 | +110% | +$25.4M |
|
22
Janux Therapeutics
JANX
$1.37B
| $46.2M | 1.24% | 4,579,818 +472,873 | +12% | +$4.77M |
|
23
Tyra Biosciences
TYRA
$675M
| $37.7M | 1.02% | 2,739,595 | – | – |
|
24
Zymeworks
ZYME
$1.12B
| $37.2M | 1% | 5,870,000 | – | – |
|
25
Replimune Group
REPL
$422M
| $36.7M | 0.99% | 2,143,036 | – | – |
|